Secukinumab shows diverging efficacy in PMR and GCA

IF 33.7 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2026-07-16 DOI:10.1038/s41584-026-01413-2

Jessica McHugh

引用次数: 0

Abstract

In two phase III trials, secukinumab improved rates of sustained remission and reduced glucocorticoid use in polymyalgia rheumatica but did not improve outcomes in giant cell arteritis.

查看原文本刊更多论文

Secukinumab对PMR和GCA的疗效存在差异

在两项III期试验中，secukinumab改善了风湿性多肌痛患者的持续缓解率，减少了糖皮质激素的使用，但没有改善巨细胞动脉炎患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.